Contextual role of E2F1 in suppression of melanoma cell motility and invasiveness
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Carcinogenesis"
DOI: 10.1002/mc.23043
Abstract: The general transcription factor E2F1 reportedly functions in a protumorigenic manner in several cancer models. We show that the genetic context of cancer cells influence E2F1's role to impede the protumorigenic role. Thirty to fifty… read more here.
Keywords: melanoma; oncogenic braf; e2f1; brafv600e ... See more keywords
ERK5 is activated by oncogenic BRAF and promotes melanoma growth
Sign Up to like & getrecommendations! Published in 2018 at "Oncogene"
DOI: 10.1038/s41388-018-0164-9
Abstract: Malignant melanoma is among the most aggressive cancers and its incidence is increasing worldwide. Targeted therapies and immunotherapy have improved the survival of patients with metastatic melanoma in the last few years; however, available treatments… read more here.
Keywords: melanoma; melanoma growth; braf; oncogenic braf ... See more keywords
The stability of R-spine defines RAF inhibitor resistance: A comprehensive analysis of oncogenic BRAF mutants with in-frame insertion of αC-β4 loop
Sign Up to like & getrecommendations! Published in 2021 at "Science Advances"
DOI: 10.1126/sciadv.abg0390
Abstract: The stabilized R-spine of oncogenic BRAF mutants impairs RAF inhibitor association and confers drug resistance. Although targeting BRAF mutants with RAF inhibitors has achieved promising outcomes in cancer therapy, drug resistance remains a remarkable challenge,… read more here.
Keywords: braf mutants; braf; oncogenic braf; resistance ... See more keywords
Abstract 3993: Efficacy of SHP2 phosphatase inhibition in cancers with nucleotide-cycling oncogenic RAS, NF1 loss and RAS-GTP-dependent oncogenic BRAF
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-3993
Abstract: Oncogenic alterations in the RAS-RAF-MEK-ERK pathway, including mutant forms of KRAS, BRAF, and loss of the tumor suppressor and RAS GTPase-activating protein (GAP) NF1, drive the growth of a wide spectrum of cancers. While BRAF… read more here.
Keywords: oncogenic braf; oncogenic ras; ras gtp; nf1 loss ... See more keywords
The Histone Deacetylase Inhibitor ITF2357 (Givinostat) Targets Oncogenic BRAF in Melanoma Cells and Promotes a Switch from Pro-Survival Autophagy to Apoptosis
Sign Up to like & getrecommendations! Published in 2022 at "Biomedicines"
DOI: 10.3390/biomedicines10081994
Abstract: Histone deacetylase inhibitors (HDACI) are epigenetic compounds that have been widely considered very promising antitumor agents. Here, we focus on the effects of the pan-HDAC inhibitor ITF2357 (Givinostat) in comparison with SAHA (Vorinostat) in melanoma… read more here.
Keywords: melanoma; itf2357; oncogenic braf; braf ... See more keywords